Marshall Wace LLP Invests $7.31 Million in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Marshall Wace LLP purchased a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 59,381 shares of the specialty pharmaceutical company's stock, valued at approximately $7,313,000. Marshall Wace LLP owned 0.10% of Jazz Pharmaceuticals at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Centre Asset Management LLC acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at about $9,335,000. Moloney Securities Asset Management LLC acquired a new position in Jazz Pharmaceuticals during the 4th quarter valued at about $464,000. Franklin Resources Inc. increased its holdings in Jazz Pharmaceuticals by 4.6% during the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company's stock worth $124,208,000 after purchasing an additional 48,708 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its stake in shares of Jazz Pharmaceuticals by 13.7% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 35,894 shares of the specialty pharmaceutical company's stock worth $4,420,000 after purchasing an additional 4,332 shares during the last quarter. Finally, BTC Capital Management Inc. raised its stake in shares of Jazz Pharmaceuticals by 9.4% in the fourth quarter. BTC Capital Management Inc. now owns 49,653 shares of the specialty pharmaceutical company's stock worth $6,115,000 after purchasing an additional 4,271 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the business's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the sale, the chief executive officer now directly owns 439,744 shares in the company, valued at approximately $53,785,088.64. The trade was a 0.34 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CMO Robert Iannone sold 7,080 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $138.60, for a total value of $981,288.00. Following the sale, the chief marketing officer now directly owns 82,024 shares in the company, valued at $11,368,526.40. This trade represents a 7.95 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 28,736 shares of company stock valued at $4,023,305 over the last three months. 4.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages recently issued reports on JAZZ. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and increased their target price for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. Barclays reissued an "overweight" rating and set a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. HC Wainwright increased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research note on Monday, March 10th. Finally, UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. One analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of "Buy" and a consensus target price of $187.71.

Jazz Pharmaceuticals Stock Up 3.0 %

JAZZ stock opened at $103.38 on Wednesday. The stock has a fifty day moving average of $126.23 and a 200-day moving average of $122.31. Jazz Pharmaceuticals plc has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The company has a market capitalization of $6.28 billion, a price-to-earnings ratio of 14.56, a PEG ratio of 1.04 and a beta of 0.42. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.